CJC-1295 With DAC
Research Hub — Aggregated Studies
MedTech Research Group aggregates published research from peer-reviewed journals, clinical trials, and academic institutions. We do not conduct original research. All studies cited below are the work of their respective authors and institutions. Sources are linked for verification.
This product is designated FOR RESEARCH USE ONLY (RUO). These compounds have not been approved or cleared under 21 U.S.C. § 505 and have not been evaluated by the FDA for safety, efficacy, or labeling for clinical, diagnostic, or therapeutic use in humans or animals.
MedTech Research Group will only fulfill orders to qualified researchers affiliated with accredited academic institutions, licensed research facilities, or organizations with active IRB/IACUC oversight.
Purchaser Restrictions
- Purchaser must be a qualified researcher at an accredited institution or licensed research facility
- This product may not be sold or redistributed to individual consumers, wellness clinics, health food stores, or retail establishments
- Not intended for human or animal consumption, diagnostic use, or therapeutic application
- Institutional affiliation and research purpose will be verified prior to order fulfillment
Distribution is limited to qualified research use in compliance with applicable federal and state law. These products bear the "For Research Use Only" designation per FDA labeling requirements (minimum 10 pt. font). Ref: 21 U.S.C. § 505; FD&C Act § 201(p) (unapproved new drug definition).
| Risk Tier | YELLOW |
| Category | Growth Hormone Axis |
| Subcategory | GH Secretagogue (Long-Acting Modified GHRH Analog) |
| Pharmacological Class | Modified Peptide Hormone Analog with Bioconjugation |
| Subclass | DAC-Modified Growth Hormone-Releasing Hormone Analog |
| Molecular Type | Bioconjugated Synthetic Peptide (Modified GRF 1-29 with Drug Affinity Complex for albumin binding) |
| Origin | Synthetic — developed by ConjuChem Biotechnologies using their proprietary DAC bioconjugation technology |
| Regulatory Status | Research Use Only. Not FDA-approved. Clinical trials conducted but not completed to approval. |
| Route of Administration | Subcutaneous injection |
| Reconstitution | Lyophilized powder; reconstitute with bacteriostatic water |
| Storage | Refrigerate (2-8°C) |
2D structure diagram from NCBI PubChem. This is the actual molecular structure of CJC-1295 With DAC.
Description
CJC-1295 with DAC is the same modified GHRH(1-29) analog as CJC-1295 without DAC, but with the addition of a Drug Affinity Complex (DAC) — a reactive chemical moiety (maleimidopropionic acid) that covalently and irreversibly binds to endogenous serum albumin after subcutaneous injection. This albumin bioconjugation strategy, developed by ConjuChem Biotechnologies, dramatically extends the peptide's circulating half-life from approximately 30 minutes (without DAC) to 6-8 days, enabling once-weekly or even less frequent dosing.
The pharmacological consequence of this extended half-life is fundamentally different from the "without DAC" version: rather than producing acute, pulsatile GH release spikes, the DAC version creates a sustained, tonic elevation of GH secretion over the entire duration of its activity. This is a critical pharmacological distinction. While both versions act through the same GHRH receptor on pituitary somatotrophs, the sustained receptor stimulation from the DAC version produces a more continuous GH/IGF-1 elevation rather than the natural spike-and-trough pattern. Some researchers and clinicians consider this less physiological, as the endogenous GH secretion pattern is inherently pulsatile, and sustained GH elevation may carry different risk profiles (particularly regarding IGF-1 levels and potential tachyphylaxis/receptor desensitization).
Clinical Context
The DAC version was originally developed as a convenience formulation — a once-weekly GH secretagogue injection. Clinical trials by ConjuChem demonstrated sustained GH and IGF-1 elevation for up to 2 weeks after a single dose. However, the clinical development program was not completed. In practice, the "without DAC" version has gained broader adoption in the peptide research community due to its more physiological pulsatile release pattern. The DAC version is typically preferred by individuals who want less frequent dosing and are less concerned about mimicking natural GH pulsatility.
- Produces sustained, non-pulsatile GH elevation — fundamentally different kinetics from the 'without DAC' version
- The 6-8 day half-life means effects (and any adverse effects) are prolonged and cannot be rapidly reversed
- IGF-1 levels may reach higher sustained levels than with the pulsatile 'without DAC' version — monitor accordingly
- Potential concern for receptor desensitization (tachyphylaxis) with continuous receptor stimulation
- Once-weekly or twice-weekly dosing is typical in research protocols
- Same pituitary dependency requirement — will not work without functional somatotroph cells
- The DAC moiety reacts with albumin in vivo; this bioconjugation is irreversible
Published Research
Published Research & Clinical Data
Peer-reviewed studies and clinical trial data related to CJC-1295 With DAC
All research below is conducted by independent institutions. MedTech Research Group provides these references for informational purposes only.
Research citations are being compiled for this compound.
Check back soon — our team is curating peer-reviewed sources.